Researchers have recently demonstrated the presence of anti-HIV-1 microRNAs (miR-28,
miR-125b, miR-150, miR-223, and miR-382) in monocytes, macrophages, and CD4+ T cells …

ABSTRACT HIV infection requires lifelong antiretroviral therapy because of the persistence
of latently infected CD4+ T cells. The induction of virus expression from latently infected cells …

Whether opiates and other drugs of abuse affect AIDS progression has been an unresolved
issue for two decades. Credible evidence has suggested that opiates may exacerbate …

Background Opioid use disorder (OUD) is prevalent among people with HIV (PWH). Opioid
agonist therapy (OAT) is the most effective treatment for OUD and is associated with …

HIV infection of the CNS causes neuroinflammation and damage that contributes to the
development of HIV-associated neurocognitive disorders (HAND) in greater than 50% of HIV …

HIV-associated neurocognitive impairment (HIV-NCI) is a debilitating comorbidity that
reduces quality of life in 15–40% of people with HIV (PWH) taking antiretroviral therapy …

Human immunodeficiency virus type 1 (HIV-1) targets CD4+ T cells and cells of the
monocyte/macrophage lineage. HIV pathogenesis is characterized by the depletion of T …

Objective: HIV type-1 (HIV-1) causes a spectrum of central nervous system (CNS)
complications; many are worsened by opiate co-exposure. Human neural progenitor cells …

Abstract Approximately 15–40% of people living with HIV develop HIV-associated
neurocognitive disorders, HAND, despite successful antiretroviral therapy. There are no …

Opioids are known to exacerbate HIV pathogenesis, however current studies have been
limited by models of HIV infection. Given that HIV causes many systemic effects via direct …